Does PAZOPANIB Cause Second primary malignancy? 81 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 81 reports of Second primary malignancy have been filed in association with PAZOPANIB (Pazopanib). This represents 0.4% of all adverse event reports for PAZOPANIB.
81
Reports of Second primary malignancy with PAZOPANIB
0.4%
of all PAZOPANIB reports
16
Deaths
22
Hospitalizations
How Dangerous Is Second primary malignancy From PAZOPANIB?
Of the 81 reports, 16 (19.8%) resulted in death, 22 (27.2%) required hospitalization, and 10 (12.3%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PAZOPANIB. However, 81 reports have been filed with the FAERS database.
What Other Side Effects Does PAZOPANIB Cause?
Death (3,767)
Diarrhoea (2,907)
Fatigue (1,883)
Nausea (1,879)
Malignant neoplasm progression (1,471)
Drug ineffective (1,135)
Decreased appetite (1,116)
Vomiting (1,072)
Hypertension (1,004)
Malaise (764)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which PAZOPANIB Alternatives Have Lower Second primary malignancy Risk?
PAZOPANIB vs PEANUT
PAZOPANIB vs PEG INTERFERON
PAZOPANIB vs PEG-INTERFERON ALFA 2A
PAZOPANIB vs PEGASPARGASE
PAZOPANIB vs PEGASYS